Suzanne E Dahlberg

Suzanne E Dahlberg

UNVERIFIED PROFILE

Are you Suzanne E Dahlberg?   Register this Author

Register author
Suzanne E Dahlberg

Suzanne E Dahlberg

Publications by authors named "Suzanne E Dahlberg"

Are you Suzanne E Dahlberg?   Register this Author

78Publications

2483Reads

39Profile Views

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Oncologist 2019 Aug 29;24(8):e749-e754. Epub 2019 Jan 29.

Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0596DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693709PMC
August 2019

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Eur J Radiol 2018 Dec 23;109:68-76. Epub 2018 Oct 23.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2018.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294464PMC
December 2018

Pragmatic approaches to address expansion cohort design.

Cancer 2018 08 5;124(16):3290-3292. Epub 2018 Jul 5.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108919PMC
August 2018

Interpretation of Results from Under-accruing Studies.

Oncologist 2018 07 8;23(7):755-756. Epub 2018 May 8.

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058329PMC
July 2018

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J Clin Oncol 2018 07 10;36(19):1905-1912. Epub 2018 May 10.

Giulia C. Leonardi, Sasha Kravets, Suzanne E. Dahlberg, and Mark M. Awad, Dana-Farber Cancer Institute; Justin F. Gainor and Roxana Azimi, Massachusetts General Hospital; Lydia Gedmintas, Brigham and Women's Hospital, Boston, MA; Mehmet Altan, MD Anderson Cancer Center, Houston, TX; Hira Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Matthew D. Hellmann, Weill Cornell Medical College, and Parker Institute for Cancer Immunotherapy, New York, NY; and Jonathan W. Riess, University of California Davis Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.0305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553840PMC
July 2018

Evaluation of End Points in Cancer Clinical Trials.

J Thorac Oncol 2018 06 26;13(6):745-747. Epub 2018 Apr 26.

Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.004DOI Listing
June 2018

Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.

Cancer Cytopathol 2018 04 5;126(4):253-263. Epub 2018 Feb 5.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncy.21973DOI Listing
April 2018

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.

Clin Cancer Res 2017 Oct 5;23(19):5737-5744. Epub 2017 Jul 5.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-1434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626605PMC
October 2017

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

JAMA Oncol 2016 Aug;2(8):1014-22

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.0173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982795PMC
August 2016

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.

Clin Cancer Res 2016 07 9;22(13):3148-56. Epub 2016 Feb 9.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/clincanres/22/
Web Search
http://clincancerres.aacrjournals.org/content/clincanres/ear
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-2377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129179PMC
July 2016

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

J Thorac Oncol 2016 Apr 25;11(4):556-65. Epub 2015 Dec 25.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.12.103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979601PMC
April 2016

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.

JAMA Oncol 2016 Mar;2(3):313-20

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819418PMC
March 2016

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

J Clin Oncol 2016 Mar 4;34(7):721-30. Epub 2016 Jan 4.

Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Jennifer C. Heng, Suzanne E. Dahlberg, Pasi A. Jänne, and Peter S. Hammerman, Dana-Farber Cancer Institute; Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Pasi A. Jänne, Peter S. Hammerman, and Lynette M. Sholl, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Suman Verma, ResearchDX, Irvine; and James Christensen, Mirati Therapeutics, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.4600DOI Listing
March 2016

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Acad Radiol 2016 Mar 8;23(3):329-36. Epub 2016 Jan 8.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2015.11.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744559PMC
March 2016

Improving Clinical Trial Efficiency: Thinking outside the Box.

Am Soc Clin Oncol Educ Book 2015 :e141-7

From the Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; National Institutes of Health, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e141DOI Listing
February 2016

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1726-35

*Department of Medical Oncology, †Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; §Harvard Medical School, Boston, Massachusetts; ‖Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. ¶Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and #Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000687DOI Listing
December 2015

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

J Thorac Oncol 2015 Jul;10(7):1099-106

*Division of Biomedical Statistics and Informatics, Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota; †Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona; ‡Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; §Department of Biostatistics and Bioinformatics, Alliance Statistics and Data Center, Duke University, Durham, North Carolina; ‖Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, NCIC Clinical Trials Group, Queen' University, Kingston, ON, Canada; #Department of Hematology & Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia; **Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, California; ††Department of Statistics for the Data Center/Operations Office, Japan Clinical Oncology Group Data Center, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan; ‡‡Department of Medical Oncology, Japanese Society of Medical Oncology, Tokyo, Japan; §§Department of Medicine, The University of Chicago Medicine and Biologic Sciences Center, Chicago, Illinois; and ‖‖Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153349
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493926PMC
July 2015

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Clin Cancer Res 2015 Jun 3;21(12):2851-60. Epub 2015 Mar 3.

Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3112DOI Listing
June 2015

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Lung Cancer 2015 Apr 4;88(1):108-11. Epub 2015 Feb 4.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.01.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355240PMC
April 2015

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-63

*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346098PMC
January 2015

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

J Natl Cancer Inst 2014 Jul 24;106(7). Epub 2014 Jun 24.

Affiliations of authors: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (SED); Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (GIS, BEJ); Department of Hematology and Oncology (JWC) and Department of Medicine (JWC), Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju163DOI Listing
July 2014

Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease.

J Vasc Surg 2014 Feb 29;59(2):409-418.e3. Epub 2013 Sep 29.

Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07415214130146
Publisher Site
http://dx.doi.org/10.1016/j.jvs.2013.07.114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946884PMC
February 2014

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Cancer 2013 Nov 23;119(21):3776-83. Epub 2013 Aug 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Centers for Outcomes and Policy Research and Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972000PMC
November 2013

Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.

Lung Cancer 2013 Jul 21;81(1):47-52. Epub 2013 Apr 21.

Hematology-Oncology Section, University of Wisconsin, Wisconsin Institutes for Medical Research, Madison, WI 53705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264629PMC
July 2013

Outcomes following infrapopliteal angioplasty for critical limb ischemia.

J Vasc Surg 2013 Jun 1;57(6):1455-63; discussion 1463-4. Epub 2013 Feb 1.

Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvs.2012.10.109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644532PMC
June 2013

The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.

Oncol Rep 2011 Jun 6;25(6):1765-72. Epub 2011 Apr 6.

School of Pharmacy, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792-5669, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2011.1249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211091PMC
June 2011

The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.

Br J Haematol 2011 Feb 7;152(4):452-9. Epub 2011 Jan 7.

Pediatric Hematology/Oncology, Children's Hospital Boston, Dana-Farber Cancer Institute Harvard Medical School Biostatistics, Dana-Farber Cancer Institute Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2010.08524.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763913PMC
February 2011

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

J Clin Oncol 2010 Feb 19;28(6):949-54. Epub 2010 Jan 19.

Department of Biostatistics and Computational Biology, CLSB 11007, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.25.4482
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.25.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834434PMC
February 2010

Population-based outcomes following endovascular and open repair of ruptured abdominal aortic aneurysms.

J Endovasc Ther 2009 Oct;16(5):554-64

Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1583/09-2743.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793420PMC
October 2009

Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.

Pediatr Blood Cancer 2009 Aug;53(2):162-7

Division of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.22076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721691PMC
August 2009

A proportional hazards cure model for the analysis of time to event with frequently unidentifiable causes.

Biometrics 2007 Dec;63(4):1237-44

Department of Biostatistics, Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1541-0420.2007.00811.xDOI Listing
December 2007